Additionally, targeted monoclonal antibody therapies against tumour biological properties—such as the expression of the human epidermal growth factor receptor 2 (HER2)—have progressively been incorporated into standard regimens, becoming an additional option that is generally well-tolerated [5,6]. The gene discussed is ERBB2; the disease is neoplasm.